TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04578418

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed collagen
Description: Hydrolyzed collagen supplementation twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy slow resistance training
Description: Heavy slow resistance training 3 times weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training
Description: Heavy slow resistance training 3 times weekly
Study: NCT02112162

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo FDG PET/MRI
Study: NCT00858403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Take tablets of Dasatinib by mouth once a day.
Study: NCT00785135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenses containing prismatic correction
Description: The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lenses not containing prismatic correction
Description: The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
Study: NCT04578418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo supplementation twice daily
Study: NCT05106374

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Complete thinking test

Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Complete walking test

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT00005775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
Study: NCT02008058

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
Study: NCT04234243

Intervention type: PROCEDURE
Intervention: cytoreduction and HIPEC
Description: cytoreduction CCR 0-1, and HIPEC close technique
Study: NCT04464941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a composite intervention with both group and individual components for oral health promotion program
Description: The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method
Study: NCT06036030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperaquine
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Study: NCT00601185

Intervention type: PROCEDURE
Intervention: confocal microscopy in vivo
Description: A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
Study: NCT02112162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03884920

Intervention type: DIETARY_SUPPLEMENT
Intervention: Polyherbal formulation
Description: Test candidate will be administered per oral before / with meal in two divided doses

Intervention type: DIETARY_SUPPLEMENT
Intervention: Polyherbal formulation
Description: Test candidate will be administered per oral before / with meal in two divided doses
Study: NCT01674062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
Study: NCT03902210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga
Description: 60 minutes per week of online yoga through Udaya.com

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Podcast
Description: 60 minutes per week of podcasts
Study: NCT06036030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Study: NCT03264716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepaSphere TACE (transarterial chemoembolization)
Description: 100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
Study: NCT02671058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortenema
Description: Hydrocortisone Administered as a Liquid Enema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Acetate
Description: Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
Study: NCT01767753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study: NCT01517919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Self-Management
Description: The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants.
Study: NCT03866265

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)
Description: Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
Study: NCT04477837

Intervention type: DRUG
Intervention: Apixaban 5 MG
Description: frequency of heavy menstrual bleeding

Intervention type: DRUG
Intervention: Rivaroxaban 20 MG
Description: frequency of heavy menstrual bleeding

Intervention type: DRUG
Intervention: Edoxaban 60 MG
Description: frequency of heavy menstrual bleeding

Intervention type: DRUG
Intervention: Dabigatran 150 Mg Oral Capsule
Description: frequency of heavy menstrual bleeding
Study: NCT02745600

Intervention type: DEVICE
Group type: OTHER
Intervention: RFA therapy simulator
Description: Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
Study: NCT06036030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Momordica Charantia Extract
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Study: NCT04061161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide
Description: Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
Study: NCT03187951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Assessments
Description: After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
Study: NCT04061161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
Study: NCT03749356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TacroBell SR cap.
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.
Study: NCT02928822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based sensorimotor aphasia therapy
Description: VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (conventional aphasia rehabilitation)
Description: 8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
Study: NCT02886689

Intervention type: DRUG
Intervention: TNF-alpha antagonist and other biotherapy
Study: NCT02425644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponesimod
Description: film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriflunomide
Description: film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
Study: NCT02366598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp shake
Description: Hemp protein shake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp shake
Description: Hemp protein shake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soybean shake
Description: Soybean protein shake
Study: NCT02133235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: auscultation
Description: insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
Study: NCT00872716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: 100 mg single-dose Quetiapine XR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02654327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VV-ECCO2R to enable lower tidal volume mechanical ventilation
Description: In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
Study: NCT01383200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine drop
Description: 0.5% Tetracaine Right eye / 2% Lidocaine Left eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine drop
Description: 0.5% Tetracaine Right eye / 2% Lidocaine Left eye
Study: NCT00474188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013 (lenalidomide)
Description: Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
Study: NCT03458845

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scan
Description: The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scan
Description: The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
Study: NCT00106106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NMR-spectroscopy
Description: Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NMR-spectroscopy
Description: Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral acamprosate
Description: For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Study: NCT00338390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Change tenofovir to abacavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir+Lamivudine
Description: Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
Study: NCT01437735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po
Study: NCT02366598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean shake
Description: Soybean protein shake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-protein shake
Study: NCT01437735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 10 mg po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01769222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given intratumorally
Study: NCT01823510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin
Description: Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + Aspirin
Description: Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
Study: NCT01927302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Naming Objects
Description: Treatment will be administered from week 0 until week 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Improving Spelling Abilities
Description: Treatment will be administered from week 0 until week 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Improving Sentence Processing
Description: Treatment will be administered from week 0 until week 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: No treatment will be administered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: No treatment will be administered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: No treatment will be administered.
Study: NCT00766441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: tablet, 100mg, once daily, 4 weeks
Study: NCT01383200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: 0.5% Tetracaine Left eye / 2% Lidocaine Right eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: 0.5% Tetracaine Left eye / 2% Lidocaine Right eye
Study: NCT04592380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1: Clevidipine (double-blinded)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stage 1: Placebo (double-blinded)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2: Clevidipine (open-label)
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stage 2: Standard of Care (open-label)
Description: Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
Study: NCT03556683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline
Description: 4 mL of 3% hypertonic saline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline
Description: 4 mL of 7% hypertonic saline